Health technology assessments (HTAs) and health economic evaluations have become a pivotal fixture in market access decisions for therapeutics and biotech applications. However, market access does not guarantee that patients are actually able to take advantage of these new developments. In a recorded Cel for Pharma webinar, Professor Lieven Annemans shares his HTA expertise to help attendees learn about how health economic evaluations actually impact patients and providers.
According to Cel for Pharma, ”Prof. Dr. Lieven Annemans has participated in more than 400 health economic evaluations in over 20 countries across a wide spectrum of therapeutic areas. He has also been involved as an expert in a large number of Health Technology Assessments (HTAs) and is actively involved in HTA on a European level.”
Click here to sign up and watch the free webinar.
(Source: Cel for Pharma, January 20th, 2022)